Sep 07, 2023 / 10:00AM GMT
Andrew Newland - ANGLE plc - Chief Executive
Good morning, everybody, and welcome to ANGLE's half year interim results for the June 30, 2023. I must say I'm pleased to be in London with actually a pretty full room of analysts, which is great. Maybe we really are finally putting COVID behind us.
Clearly, it's been a very difficult set of conditions externally, not just for ANGLE, obviously, but for healthcare stocks and indeed, for our investors and shareholders and investment funds interested in our story. It's also been pretty challenging for some of the biopharma customers that we're dealing with.
But despite all of these adverse external conditions, I'm very pleased to report that ANGLE has had an excellent half year, and we've made progress on multiple different areas that are critical to our future development.
So I'm pleased to be able to re-confirm that we're well focused on our mission to support personalized cancer care with the only FDA cleared platform, which is available to provide the best sample intact living cancer cells from patient blood.
And
Half Year 2023 Angle PLC Earnings Call Transcript
Feb 12, 2024
Already have an account? Log in
Get the full story
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent 
4.6 out of 5 
Trustpilot
Trustpilot
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers